Stocky turns companies like NewAmsterdam Pharma Company N.V into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Avoid. Nams' 12/100 Value Compounder Score reflects near-zero revenue and weak fundamentals, while clinical-stage risk is extreme: obicetrapib represents 95%+ of R&D focus with Phase 3 PREVAIL outcomes trial as make-or-break catalyst. Leadership alignment (55/100) offers limited comfort given the binary bet on a single asset with no commercial validation.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for NewAmsterdam Pharma Company N.V:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 21/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates NewAmsterdam Pharma Company N.V (NAMS) at 21/100 — an Avoid — fundamentals or risks are too weak. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Avoid. Nams' 12/100 Value Compounder Score reflects near-zero revenue and weak fundamentals, while clinical-stage risk is extreme: obicetrapib represents 95%+ of R&D focus with Phase 3 PREVAIL outcomes trial as make-or-break catalys
NAMS's current Stocky Verdict is 21/100, placing it in the "Avoid" band. This composite combines a 12/100 Compounder score, 55/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for NewAmsterdam Pharma Company N.V yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
NewAmsterdam Pharma Company N.V scores 55/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
NewAmsterdam Pharma Company N.V's Vulnerability Profile scores 25/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to NewAmsterdam Pharma Company N.V.
Sign up free and unlock the full analysis on NAMS — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for NAMS in the app.
